Cancer Drugs Fund seems to help pharmaceuticals giant Roche most

Roche, the Swiss pharmaceutical company at the centre of the row overcancer drugs pricing, played a significant part in the genesis ...

Read more →

pCODR recommends the funding of trastuzumab emtansine (Kadcyla) for female patients with HER-2 positive breast cancer

[:content [\1 \0 \space \J \a \n \u \a \r \y \space \2 \0 \1 \4 \space \- \space \T \h \e \space \p \C \O \D \R \space \E \x \p \e \r \t \space \R \e \v \i \e \w \space \C \o \m \m \i \t \t \e \e \space \( \p \E \R \C \) \space \h \a \s \space \r \e \c \o \m \m \e \n \d \e \d \space \t \h \e \space \f \i \n \d \i \n \g \space \o \f \space \t \r \a \s \t \u \z \u \m \a \b \space \e \m \t \a \n \s \i \n \e \space \( \K \a \d \c \y \l \a \) \space \f \o \r \space \p \a \t \i \e \n \t \s " ..."]]
Read more →

Drug recommended to help cut drink dependence

NICE has approved the use of nalmefene to help people who are dependent on alcohol to cut down on the ...

Read more →

Pharmaceutical Benefits Scheme listing of ivacaftor (Kalydeco) for cystic fibrosis

A stakeholder meeting was held on 31 July 2014 to discuss the Pharmaceutical Benefits Scheme (PBS) listing of ivacaftor (Kalydeco) ...

Read more →

Public consultation on the post-market review of Authority Required PBS listings

Public consultation on the Authority Required PBS medicines is now open and interested stakeholders can provide comments about any of ...

Read more →

New OECD data shows Australia lagging in investing in medicines

Data newly released by the Organisation for Economic Cooperation and Development (OECD) reveals that Australia is not matching other industrialised ...

Read more →

Hospira's Inflectra (infliximab) now available in Canada

Hospira, Inc., a global leader in biosimilars and the world's leading provider of injectable drugs and infusion technologies, announces the ...

Read more →

Cosentyx: first IL-17A antagonist for moderate-to-severe plaque psoriasis now approved in Canada

Novartis announced today that Health Canada has approved Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis in adult ...

Read more →

New Zealand Pharmaceutical Schedule - 1 April 2015 update

The April 2015 issue of the New Zealand Pharmaceutical Schedule is out and now in effect. There are no new major ...

Read more →

Québec becomes first Canadian province to add Victoza to the drug benefit formulary for the treatment of type 2 diabetes

Novo Nordisk today announces that the Québec government has approved the inclusion of Victoza (liraglutide), the first once-daily human glucagon-like peptide-1 ...

Read more →

Decision to fund rifaximin (Xifaxan) for hepatic encephalopathy

14 July 2014 - PHARMAC is pleased to announce the decision to award the tender to Norgine for Sole Subsidised Supply ...

Read more →

Parliamentary Budget Office confirms PBS spending not the villain

[:content [\1 \2 \space \D \e \c \e \m \b \e \r \space \2 \0 \1 \3 \space \- \  \F \i \g \u \r \e \s \space \c \o \n \t \a \i \n \e \d \space \i \n \space \a \space \r \e \p \o \r \t \space \r \e \l \e \a \s \e \d \space \t \h \i \s \space \w \e \e \k \space \b \y \space \t \h \e \space \P \a \r \l \i \a \m \e \n \t \a \r \y \space \B \u \d \g \e \t \space \O \f \f \i \c \e \space \c \o \n \f \i \r \m \space \t \h \a \t \space \t \h \e \space \P \h \a \r \m \a \c \e \u \t \i \c \a \l " ..."]]
Read more →

James Raftery: NICE and value-based pricing - is this the end?

Since Andrew Lansley announced in 2010 that the NHS would in future use “value based pricing” in its purchases of pharmaceuticals, civil ...

Read more →

Saskatchewan to fund treatment with Aubagio for relapsing-remitting multiple sclerosis

Genzyme, a Sanofi company, announced today that the Saskatchewan Drug Program has included Aubagio (teriflunomide) 14 mg on the provincial drug ...

Read more →

Agenda for 15 April 2015 TC meeting

The agenda for the 15 April 2015 TC meeting is now available. The Commission will consider the following technologies: ...

Read more →